ReviewMolecular neurobiology2026
Extracellular Vesicles in Migraine: Biomarkers and Therapeutics.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicle biomarkers: current status and future perspectives as novel tools in liquid biopsy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis and therapeutic evaluation of migraine have long relied on subjective clinical descriptions, lacking objective, stable, and quantifiable biological markers. Extracellular vesicles (EVs), which carry specific bioactive molecules, have been recognized in recent years as a potential breakthrough in research due to their role in intercellular communication, the stability of their contents, and their reflection of pathological states. This article comprehensively evaluates studies on changes in EVs and their contents in migraine patients, discusses methods for isolating and characterizing EVs, sample sources, and other issues, and critically analyzes existing evidence regarding EVs as biomarkers and therapeutic carriers for migraine. Current research suggests alterations in miRNA and protein profiles in EVs of migraine patients, but these findings generally face reproducibility issues. Finally, the article also elaborates on the numerous challenges encountered during clinical translation. Overall, EVs provide a promising yet immature new perspective for migraine research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.